If it can continue lining up positive data readouts and regulatory approvals, its financial results will eventually improve, and its stock price could jump. Pfizer and Moderna are very different ...

Moderna faces challenges with respiratory vaccine sales and strong competition. Click here to read an analysis of MRNA stock ...

The update includes Pfizer Inc.’s (NYSE ... The biotech sector, being particularly... Moderna stock and other vaccine makers are under pressure after Peter Marks resigned from the FDA.

Pfizer’s (PFE) stock has fallen ill since the COVID-19 pandemic waned, and it is still experiencing some aftereffects. The ...

Pfizer Inc. closed 28.57% short of its 52-week high of $31.54, which the company reached on July 30th.

CDC panel expands Pfizer and GSK RSV vaccine use to high-risk adults 50–59, building on earlier recommendations for older ...

and its stock price could jump. So, in my view, Pfizer is the better option, except perhaps for high-risk, growth-oriented investors. Moderna has more upside if some of its pipeline candidates ...

However, Pfizer and Moderna's revenue and earnings dropped ... Lastly, Pfizer is a solid dividend stock. It now offers a beefy 6.8% yield, and has increased its payouts by 53.6% in the past ...